[Insulin resistance treatments in the future]

Related Experiment Video

Updated: Jul 10, 2026

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
08:13

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)

Published on: January 7, 2018

Jacques Philippe1, François Jornayvaz

  • 1Service d'Endocrinologie, Diabétologie et Nutrition, Hôpitaux Universitaires de Genève, 1211 Genève 14, Suisse. jacques.philippe@hcuge.ch

Journal De La Societe De Biologie
|November 6, 2007
PubMed

Insights

Current type 2 diabetes treatments often fail due to disease progression and patient adherence challenges. New therapies targeting insulin resistance and secretion are crucial for better blood glucose control and managing complications.

Area of Science:

  • Endocrinology and Metabolism
  • Pharmacology
  • Cellular Biology

Background:

  • Current type 2 diabetes (T2D) treatments show limitations in long-term metabolic control.
  • Disease progression and patient self-management challenges contribute to treatment failure.
  • Novel therapeutic strategies are needed to address underlying T2D pathophysiology.

Purpose of the Study:

  • To review current and future developments in T2D treatment.
  • To focus on therapeutic targets aimed at decreasing insulin resistance.
  • To explore new targets in appetite control, insulin signaling, and cellular energy balance.

Main Methods:

  • Review of recent scientific literature on T2D therapeutic targets.
  • Discussion of identified targets including the endocannabinoid system, glucagon-like-peptide 1 (GLP-1), and AMP kinase.
  • Analysis of the role of these targets in insulin resistance and secretion.

Main Results:

  • Multiple novel therapeutic targets have been identified in the last decade.
  • Targets include appetite regulators (endocannabinoid system, GLP-1) and insulin signaling pathways.
  • Cellular energy balance regulators like AMP kinase are also key targets.

Conclusions:

  • Emerging treatments focusing on insulin resistance offer promise for T2D management.
  • Targeting appetite control and cellular energy metabolism could improve glycemic control.
  • These advancements are expected to lead to better management of T2D and its associated complications.

More Related Videos

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...